Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

  • End date
    Aug 29, 2024
  • participants needed
  • sponsor
    TG Therapeutics, Inc.
Updated on 29 May 2022
measurable disease
b-cell lymphoma
refractory b-cell non-hodgkin lymphoma
refractory classical hodgkin lymphoma


Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.


This study will evaluate the safety profile, pharmacokinetics, and efficacy of single-agent cosibelimab as well as the combination of Cosibelimab + Ublituximab + Bendamustin.

Condition B-cell Non Hodgkin Lymphoma, Richter's Transformation
Treatment TG-1501, Cosibelimab, Cosibelimab + Ublituximab + Bendamustine combination
Clinical Study IdentifierNCT03778073
SponsorTG Therapeutics, Inc.
Last Modified on29 May 2022


Yes No Not Sure

Inclusion Criteria

Histologically confirmed relapsed or refractory B-cell non-Hodgkin lymphoma (NHL)
Measurable disease and adequate organ function as specified in the protocol

Exclusion Criteria

Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or prior therapy with bendamustine
Subjects receiving cancer therapy or investigational drug within 21 days of Cycle 1 Day 1
Prior autologous stem cell transplant within 3 months
Active Hepatitis B or Hepatitis C
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note